JP2013501722A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013501722A5 JP2013501722A5 JP2012523949A JP2012523949A JP2013501722A5 JP 2013501722 A5 JP2013501722 A5 JP 2013501722A5 JP 2012523949 A JP2012523949 A JP 2012523949A JP 2012523949 A JP2012523949 A JP 2012523949A JP 2013501722 A5 JP2013501722 A5 JP 2013501722A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- subject
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 102000001307 androgen receptors Human genes 0.000 claims 4
- 108010080146 androgen receptors Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010020112 Hirsutism Diseases 0.000 claims 1
- 206010054834 Hypergonadism Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- -1 glidants Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000002966 varnish Substances 0.000 claims 1
- 239000001993 wax Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23225709P | 2009-08-07 | 2009-08-07 | |
| US61/232,257 | 2009-08-07 | ||
| US26126509P | 2009-11-13 | 2009-11-13 | |
| US61/261,265 | 2009-11-13 | ||
| PCT/US2010/044570 WO2011017534A2 (en) | 2009-08-07 | 2010-08-05 | Treatment of prostate cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015221564A Division JP2016074687A (ja) | 2009-08-07 | 2015-11-11 | 前立腺癌の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013501722A JP2013501722A (ja) | 2013-01-17 |
| JP2013501722A5 true JP2013501722A5 (enExample) | 2013-09-19 |
Family
ID=43535282
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012523949A Pending JP2013501722A (ja) | 2009-08-07 | 2010-08-05 | 前立腺癌の処置 |
| JP2015221564A Pending JP2016074687A (ja) | 2009-08-07 | 2015-11-11 | 前立腺癌の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015221564A Pending JP2016074687A (ja) | 2009-08-07 | 2015-11-11 | 前立腺癌の処置 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US8791094B2 (enExample) |
| EP (1) | EP2461814A4 (enExample) |
| JP (2) | JP2013501722A (enExample) |
| KR (1) | KR20120056267A (enExample) |
| AU (1) | AU2010279398A1 (enExample) |
| BR (1) | BR112012002797A2 (enExample) |
| CA (1) | CA2770092A1 (enExample) |
| WO (1) | WO2011017534A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100048524A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| WO2009129208A2 (en) * | 2008-04-14 | 2009-10-22 | University Of Maryland, Baltimore | Compositions and methods of inducing endoplasmic reticulum stress reponse |
| EP2393827B1 (en) | 2009-02-05 | 2015-10-07 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| PE20121048A1 (es) | 2009-06-26 | 2012-08-25 | Novartis Ag | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 |
| EP2461814A4 (en) | 2009-08-07 | 2012-12-05 | Tokai Pharmaceuticals Inc | PROSTATE CANCER TREATMENT |
| MX359399B (es) | 2011-04-28 | 2018-09-27 | Novartis Ag | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. |
| JP2014523445A (ja) * | 2011-07-18 | 2014-09-11 | トーカイ ファーマシューティカルズ，インク． | 前立腺癌を処置するための新規な組成物及び方法 |
| US20130203615A1 (en) * | 2011-08-05 | 2013-08-08 | Gen-Probe Incorporated | Antiandrogen therapy monitoring methods and compositions |
| WO2013071177A1 (en) * | 2011-11-10 | 2013-05-16 | Tokai Pharmaceuticals, Inc. | Methods and compositions for inhibition of androgen receptor activity |
| CA2904170A1 (en) | 2013-03-14 | 2014-09-25 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
| KR20160058774A (ko) | 2013-08-12 | 2016-05-25 | 토카이 파마슈티컬, 아이엔씨. | 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커 |
| WO2015170336A1 (en) | 2014-05-09 | 2015-11-12 | Council Of Scientific & Industrial Research | 16α-HETEROARYL PREGNENOLONE ACETATE AND A PROCESS FOR PREPARATION THEREOF |
| WO2016119742A1 (zh) * | 2015-01-29 | 2016-08-04 | 苏州晶云药物科技有限公司 | (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法 |
| ITUA20164043A1 (it) * | 2016-06-01 | 2017-12-01 | Ind Chimica Srl | Processo per la preparazione di 3β-idrossi-17-(1H-benzimidazol-1-il)androsta-5,16-diene |
| WO2017208132A1 (en) * | 2016-06-01 | 2017-12-07 | Industriale Chimica S.R.L. | Process for the preparation of galeterone |
| US11756656B2 (en) * | 2018-06-14 | 2023-09-12 | Astrazeneca Uk Limited | Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition |
| US12337004B2 (en) * | 2019-04-27 | 2025-06-24 | Health Research, Inc. | Coumarin-modified androgens for the treatment of prostate cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH621803A5 (enExample) * | 1974-08-08 | 1981-02-27 | Siphar Sa | |
| US5604213A (en) * | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| NZ266640A (en) * | 1993-04-30 | 1998-01-26 | Pacific Northwest Research Fou | Diagnosing genotoxic or carcinogenic status by analysing cellular redox potential where increased risk is indicated when the potential favours oxidatively derived modified nucleotides |
| US5994335A (en) * | 1997-10-17 | 1999-11-30 | The University Of Maryland, Baltimore | 17-azolyl steroids useful as androgen synthesis inhibitors |
| US20030054053A1 (en) * | 2001-09-20 | 2003-03-20 | Charles Young | Methods and compositions for inhibiting the proliferation of prostate cancer cells |
| PT1660115E (pt) | 2003-07-29 | 2011-08-24 | Dompe Spa | ASSOCIAÇÃO FARMACjUTICA DE G-CSF E DE PLGF ÚTIL NA MOBILIZAÇÃO DE CÉLULAS ESTAMINAIS DO SANGUE |
| JP4585201B2 (ja) * | 2004-01-23 | 2010-11-24 | 丸善製薬株式会社 | アンドロゲン受容体結合阻害剤、養毛剤、皮脂分泌抑制剤及び前立腺肥大抑制剤 |
| JP5130453B2 (ja) | 2005-03-02 | 2013-01-30 | ユニバーシティ オブ メリーランド，ボルティモア | 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性 |
| WO2008154382A1 (en) * | 2007-06-06 | 2008-12-18 | University Of Maryland, Baltimore | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| US20100048524A1 (en) * | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| EP2461814A4 (en) | 2009-08-07 | 2012-12-05 | Tokai Pharmaceuticals Inc | PROSTATE CANCER TREATMENT |
-
2010
- 2010-08-05 EP EP10807167A patent/EP2461814A4/en not_active Withdrawn
- 2010-08-05 KR KR1020127006009A patent/KR20120056267A/ko not_active Ceased
- 2010-08-05 BR BR112012002797A patent/BR112012002797A2/pt not_active IP Right Cessation
- 2010-08-05 WO PCT/US2010/044570 patent/WO2011017534A2/en not_active Ceased
- 2010-08-05 CA CA2770092A patent/CA2770092A1/en not_active Abandoned
- 2010-08-05 JP JP2012523949A patent/JP2013501722A/ja active Pending
- 2010-08-05 US US12/851,070 patent/US8791094B2/en not_active Expired - Fee Related
- 2010-08-05 AU AU2010279398A patent/AU2010279398A1/en not_active Abandoned
-
2014
- 2014-06-24 US US14/313,894 patent/US9156878B2/en not_active Expired - Fee Related
-
2015
- 2015-03-02 US US14/635,469 patent/US20150166599A1/en not_active Abandoned
- 2015-03-02 US US14/635,415 patent/US20150203528A1/en not_active Abandoned
- 2015-11-11 JP JP2015221564A patent/JP2016074687A/ja active Pending
-
2017
- 2017-02-23 US US15/440,623 patent/US20170157148A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013510856A5 (enExample) | ||
| JP2015527360A5 (enExample) | ||
| AU2012330885B2 (en) | Oral immediate release formulations for substituted quinazolinones | |
| JP2011068653A5 (enExample) | ||
| TWI598098B (zh) | 脂質異常症治療劑 | |
| JP2014532638A5 (enExample) | ||
| JP2012516900A5 (enExample) | ||
| JP2016522835A5 (enExample) | ||
| JP2019516684A5 (enExample) | ||
| HUP0200409A2 (en) | Valdecoxib compositions, process for their preparation and their use | |
| KR20140075754A (ko) | 7-[4-(4-벤조[ｂ]티오펜-4-일-피페라진-1-일)부톡시]-1Ｈ-퀴놀린-2-온 또는 그 염을 함유하는 정제 | |
| TW200538115A (en) | New pharmaceutical compositions for the treatment of sexual disorders | |
| IL314360B2 (en) | Method for the synthesis of thyroid hormone analogs and their polymorphs | |
| EA200901277A1 (ru) | Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина | |
| CA2687741A1 (en) | Stabilized amorphous forms of imatinib mesylate | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2019506387A5 (enExample) | ||
| TW201513864A (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2011046708A5 (enExample) | ||
| WO2013032558A4 (en) | Products for anti-inflammation support | |
| FR3056108B1 (fr) | Utilisation des harringtonines dans le traitement cancer du sein, notamment triple-negatif | |
| JP2016514706A5 (enExample) | ||
| CN111315378A (zh) | 包含lsz102和瑞博西尼的药物组合 | |
| US12396969B2 (en) | Compounds and methods for the treatment of parasitic infections | |
| PH12022550917A1 (en) | Use of phenylquinolinones and flavonoid derivatives for treating neuropathic pain |